|
||
World Equity NewsEquities Org UKMortgages, insurance, and loans for the self-employed and students Equities Org equities news has moved! How to quickly sell your house London equity markets make small gains Eurofirst highest since May 2002 Eurofirst makes small gains as Xetra Dax down Eurofirst slightly higher as elections approach London strong on double witching hour NYSE sees little movement on investor caution European equities investors worried by elections NYSE equities down on economic data Nikkei down on post-election profit-taking Nikkei down on post-election profit-taking Economic concerns hit Eurofirst and Xetra Dax Japanese elections boost Tokyo indices Xetra Dax sees fall in Allianz Utilities focus on FTSE Dow Jones sees little movement Analysts suggest Katrina will stimulate economy Investors settled by Japanese polls Banking and utilities see gains on Eurofirst FTSE makes small gains on mergers Investors consider construction boom after hurricane Investors wait in Sunday's election Eurofirst drops from 38-month highs UK Equities down despite monetary policy decision London FTSE makes only small gains Investors consider Katrina economy impact FTSE gains to three-year high |
27/06/05Brazil threatens Abbot over drug pricingIf Abbot Laboratories will not cut the price of one of its AIDS drugs, Brazil has said that it will break the company’s patent on the drug and begin manufacturing the drug itself. Brazil is in talks with Abbot to try to convince the drug maker to cut the price of Kaltera, an anti-retroviral drug, by 42 percent. Abbot’s current price for the drug is $1.17 per pill. Brazil says that a state-owned lab could sell the drug for 68 cents per pill. Humberto Costa, Brazil’s health minister, said that if his country does break Abbot’s patent on Kaltera, it will do so only because it is in the best interest of the public. The World Trade Organization permits nations to break patents in this way if certain circumstances of national emergency exist, but critics of Brazil’s intentions say that such conditions do not exist in this case because Brazil is spending less to treat AIDS now than was the case five years ago. Abbot Laboratories said that if Brazil makes good on its threat, it could have a negative impact on research into and development of new drugs for all diseases. An official of a US drug industry lobby, the Pharmaceutical Research and Manufacturers of America, called Brazil’s threat “troubling.” The Brazilian government is also currently in discussions with Merck and Gilead Sciences, two other US drug manufacturers, concerning the prices of their AIDS drugs, and Mr. Costa said that Brazil is ready to break their patents as well if they will not lower their prices. |
USA equity market references:CategoriesArchives
Property for sale Egypt
Investment property for sale in Egypt.
Buying old mobile phones
Buying old mobile phones for cash and recycling.
Bathroom suites
Discount bathroom suites & accessories
Natural bedding
Discount natural bedding materials.
Fax consumables
Great deals on fax consumables here |
|
US Equities copyright 2005 Central Consultants : All Rights Reserved |
||